The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports
Bristol Myers to Buy Precision Oncology Co.
Turning Point Therapeutics Inc. shares traded 116% higher after the company reported it entered into a definitive agreement to be acquired by Bristol Myers Squibb Co. in an all-cash transaction for $76.00 per share.Precision Oncology Co. Signs $1.325B Licensing Deal
Repare Therapeutics Inc. shares traded more than 50% higher after the company reported it entered into a worldwide license and collaboration agreement with Roche AG for its anti-tumor drug camonsertib (RP-3500). The agreement includes an upfront payment of $125 million and up to an additional $1.2 billion in development, sales and royalties if certain milestones are achieved.Important Data for COVID Drug Candidate Due This Month
Research Report
The "update should be important for determining EDP-235's potential to tap into this large market," noted a ROTH Capital Partners report.
Cancer Patients Have Partial Response With Drug
Research Report
The developer of this antibody just released the results of its dose evaluation in solid tumors, noted a Wedbush report.
Cancer Targeting Drug Better Tolerated Than Others
Research Report
A comparison of safety data shows this Phase 3 treatment candidate for liposarcoma differentiates itself from competitors with its superior safety profile, noted an Oppenheimer report.
50% Revenue Growth Expected This Year for Biopharma Co.
Research Report
The company is pursuing several strategies to boost revenue, including clinical trials to possibly expand the label of one of its approved dermatological drugs, noted a ROTH Capital Partners report.
Target Price on Drug Co. Suggests Possible Huge Returns
Research Report
Through H2/22, this biopharma intends to keep advancing its psychedelic drug formulations for major depression, noted a ROTH Capital Partners report.
Innoviva Buys Remaining Shares in Advanced Antibiotic Co.
Shares of Entasis Therapeutics traded 21% higher after the company reported it entered into a definitive merger agreement with Innoviva Inc., whereby Innoviva will acquire all outstanding shares of Entasis that it does not already own for $2.20 per share.H2/22 Slated to Be Catalyst Rich for Pharma Co.
Research Report
Streetwise looks over the latest events surrounding Syros Pharmaceuticals after a Roth Capital Partners report shared that its newest updates could bolster the cash position of the firm and, thus, allow it to continue advancing all of its clinical programs.
New Improved Drug Expected to Get FDA Approval Next Month
Research Report
Greenlighting of its medication for urea cycle disorders is the first of a trio of catalysts anticipated for this U.S. pharma firm in 2022, noted a ROTH Capital Partners report. Streetwise reviews the newest updates in this drug development and the company's stock.
US Pharma Co. Granted FDA Approval for IV Smallpox Drug
SIGA Technologies Inc. shares traded 30% higher after the company reported that the U.S. FDA has granted approval for an intravenous (IV) formulation of its TPOXX® (tecovirimat) for use in treating smallpox.Firm Reports Encouraging Trial Results in Cystinosis
Research Report
New data from a Wedbush report shows that study patients experienced improvements in visual-motor integration, motor coordination, and visual perception. Streetwise Reports takes a deeper look at Avrobio Inc.
EU Co. Secures Smallpox Vaccine Order to Target Monkeypox
Shares of Danish vaccine company Bavarian Nordic A/S traded 70% higher after the company advised that it had secured a contract for its IMVANEX® smallpox vaccine from an undisclosed country in Europe for use in addressing newly confirmed cases of monkeypox.Coverage Launched on Co. in Alzheimer's Drug Space
Research Report
This biopharma's therapeutic candidates for central nervous system diseases stand out because of their selective and specific mechanism of action, noted a Leede Jones Gable report.
Clinical Catalysts for Biotech's Stock On Track for Mid 2022
Research Report
Upcoming potential stock-moving events include new data concerning the company's lead therapeutic candidate for age-related eye diseases, noted a ROTH Capital Partners report.
Biopharma Co. to Launch Two Clinical Trials This Year
Research Report
Success in either program, atopic dermatitis or asthma, "could lead to multiblockbuster sales," noted a ROTH Capital Partners report.
Japan Pharma Co. Invests $275 Million in U.S. Oncology Firm
Cullinan Oncology Inc. shares traded 23% higher yesterday after the company reported it entered into a strategic investment, development and licensing agreement with Taiho Pharmaceutical Co. Ltd. of Japan for its CLN-081/TAS6417 for use in treatment of non-small cell lung cancer.First Results From Biotech Co.'s Lymphoma Program Are Impressive
Research Report
This data will be presented at the 2022 annual meeting of the European Hematology Association on June 11th, noted a ROTH Capital Partners report.
Pfizer Offers $11.6B to Buy Biopharma Co.
Shares of Biohaven Pharmaceutical Holding Co. Ltd. traded almost 70% higher after the company reported it agreed to be acquired by Pfizer Inc. for $148.50 per share in cash plus future royalty opportunities.Biopharma Co. Licenses Orphan Drug to UK Firm for $450M
Intercept Pharmaceuticals Inc. shares traded 20% higher after the company reported it entered into a $450 million licensing agreement with Advanz Pharma in markets outside of the U.S. for Ocaliva® for use in treatment of primary biliary cholangitis, a progressive and chronic autoimmune disease which affects the liver.Analyst Says Avivagen Is a Strong Buy
Contributed Opinion
With Avivagen's breakthrough product relishing in its success, Analyst Clive Maund reviews if he believes it is now a formidable contender as a Buy.
Pilot Launch of VLN Cigarettes in Progress
Research Report
These "very low nicotine" tobacco products will be an alternative for smokers when the FDA effects its imminent menthol cigarette ban, noted a ROTH Capital Partners report.
Biotech Co. Advances COVID-19 Vaccines Toward Approval
Research Report
They include booster vaccines for different age groups of children and an Omicron-targeting booster for adults, noted an H.C. Wainwright & Co. report.
Could a New Prescription Drug Treat This Common Ailment?
Research Report
The combination drug Halo-Lido is poised to be the first-of-its-kind prescription treatment approved by the U.S. Food and Drug Administration for this prevalent medical condition, noted a DawsonJames report.